stockrow
Friday 6 November 2026
Export STIM’s income statement to Excel — free account
Neuronetics, Inc.
STIM Healthcare Medical Devices
Neuronetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.2 million, up 99.2% from fiscal 2024.
- Revenue
- +12.5%
- EPS
- +84.6%
- Free cash flow
- +237.7%
- Total debt
- −5.97%
Quarter to September 2026, against a year earlier
2.18
0.25
−10.29%
Follow STIM
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 3 | 4 | 4 |
| (134.39%) | (131.16%) | (114.52%) | (85.85%) | ||
| (27.61%) | (27.76%) | (22.87%) | (16.64%) | ||
ROIC |
(34.06%) | (31.09%) | (24.64%) | (16.72%) | |
Return on Tangible Assets |
(109.87%) | (163.03%) | (107.21%) | (76.39%) | |
Average Days of Receivables |
41.34 | 39.02 | 38.29 | 0.00 | |
Free Cash Flow per Share |
(0.32) | (0.19) | (0.15) | (0.11) | |
Free Cash Flow |
(21.17) | (13.56) | (11.22) | (8.28) | |
Capital Expenditures |
(0.80) | (0.75) | (0.92) | — | |
| Other line items | |||||
Cash ROIC |
(16.75%) | (13.89%) | (10.36%) | (7.38%) | |
Accounts Receivable Turnover |
7.24 | 7.04 | 7.23 | 0.00 | |
Accounts Payable Turnover |
7.05 | 7.92 | 7.13 | 7.32 | |
Inventory Turnover |
17.92 | 17.97 | 15.11 | 17.01 | |
Average Days of Payables |
51.01 | 52.88 | 57.45 | 46.15 | |
Days of Inventory on Hand |
20.55 | 21.81 | 25.45 | 22.90 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4.41% | 4.18% | 3.78% | 3.48% | |
Selling, General and Administrative Expense of Revenue |
65.14% | 63.18% | 60.08% | 56.59% | |
Share Based Compensation of Revenue |
4.59% | 4.67% | 3.84% | 2.96% | |
Interest Coverage |
(3.74) | (3.36) | (2.56) | (1.69) | |
Operating CF/Net income |
0.52 | 0.34 | 0.34 | 0.36 | |
Depreciation/Fixed assets |
0.78 | 0.85 | 0.90 | 0.94 | |
Capex/Depreciation |
(0.23) | (0.23) | (0.29) | 0.00 | |
Revenue per Share |
2.26 | 2.18 | 2.12 | 2.07 | |
Operating CF per Share |
(0.31) | (0.18) | (0.14) | (0.11) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.00 |
Columns are period end dates · fundamentals updated 4 Nov 2026